Compare Carvana Co (CVNA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Sanofi SA — how do they compare? Carvana Co trades at $71.96 (market cap $79.17B), while Sanofi SA trades at $43.62 (market cap $104.30B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays a 5.55% dividend while Carvana Co pays none. Which is the better fit depends on your goals.
| CVNA | SNY | |
|---|---|---|
Market Cap | $79.17B | $104.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $52.34 |
52-Week Low | $56.27 | $41.33 |
Enterprise Value | $81.65B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $72.01, down 2.95% today, as investors digest recent earnings and guidance. The stock shows strong technical momentum with bullish moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, CVNA delivered impressive Q2 2026 results with revenue up 52% to $7.38 billion and record retail unit growth of 38%, though full-year EBITDA guidance of $2.70–$3.0 billion disappointed some investors.
While Carvana demonstrates robust revenue growth and improving profitability, its premium valuation (P/E 38.1, EV/EBITDA 575.03) and execution risks warrant caution. The company's debt reduction from 89.99% to 41.12% debt-to-asset ratio since 2022 is positive, but competitive pressures and margin compression remain key concerns. Analyst consensus suggests 21% upside to the $87.18 price target.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
